Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Skye Bioscience Inc SKYE

Healthcare Biotechnology
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation... see more

Recent & Breaking News (NDAQ:SKYE)

Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups

GlobeNewswire June 7, 2022

Skye Bioscience to Present at LD Micro Invitational

Newsfile June 6, 2022

Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics

GlobeNewswire May 12, 2022

Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience

Newsfile May 12, 2022

Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal

GlobeNewswire May 5, 2022

Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research

GlobeNewswire April 28, 2022

Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate

GlobeNewswire March 3, 2022

Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

GlobeNewswire February 16, 2022

Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model

GlobeNewswire February 1, 2022

Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022

GlobeNewswire January 10, 2022

Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference

GlobeNewswire January 4, 2022

Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD

GlobeNewswire December 15, 2021

Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

GlobeNewswire October 21, 2021

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

GlobeNewswire October 12, 2021

Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

GlobeNewswire October 7, 2021

Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

GlobeNewswire October 5, 2021

Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

GlobeNewswire September 29, 2021

Skye Bioscience Announces $7.0 Million Registered Direct Offering

GlobeNewswire September 27, 2021

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

GlobeNewswire September 21, 2021

Skye Bioscience Announces Special Virtual Investor Presentation

GlobeNewswire September 14, 2021